CapsoVision 2025 Q3 Earnings Narrowed Losses but Wider Net Loss

CapsoVision (CV) reported its fiscal 2025 Q3 earnings on Nov 13, 2025, with revenue rising 19.3% year-over-year to $3.54 million. However, the company missed revenue expectations by $0.14 million and EPS by $0.04, while the net loss widened despite improved per-share losses. Management reiterated strategic focus on AI diagnostics and pancreatic cancer detection but provided no specific financial guidance.

Revenue

Revenue surged to $3.54 million in Q3 2025, driven by a 19.3% year-over-year increase. Products accounted for $3.30 million, reflecting strong demand for CapsoCam Plus capsules, while Services contributed $234,000. The total revenue growth was fueled by a 31% rise in new accounts and higher small-bowel imaging adoption.

Earnings/Net Income

CapsoVision narrowed its per-share loss to $0.17 in Q3 2025 from $2.79 in the prior-year period (93.9% improvement). However, the net loss expanded to $7.92 million, a 36.7% increase from $5.79 million in 2024 Q3. The widening loss was attributed to higher operating expenses, including R&D and public-company costs. Despite a 93.9% improvement in EPS, the net loss widened by 36.7% year-over-year.

Price Action

The stock price of CapsoVision edged up 2.53% during the latest trading day, surged 18.13% during the most recent full trading week, and gained 20.90% month-to-date. Rhea-AI noted a 4.44% positive end-of-day impact following the Breakthrough Device Designation news.

Post-Earnings Price Action Review

CapsoVision’s stock experienced mixed post-earnings reactions. While the 2.53% daily gain aligned with modest optimism, the 4.44% Rhea-AI-identified positive sentiment contrasted with the 13.4% after-hours decline to $4.91. The 18.13% weekly surge and 20.90% monthly rise suggested strong short-term investor confidence, though the widened net loss and elevated operating expenses raised caution. Analysts highlighted the 31% new-account growth and strategic AI advancements as key positives, balancing concerns over regulatory risks and cash burn.

CEO Commentary

Johnny Wang, President and CEO, emphasized CapsoVision’s 19% revenue growth and 31% new-account increase in Q3. He highlighted progress in AI analytics, Breakthrough Device Designation for pancreatic cancer detection, and a higher-resolution CMOS partnership with Canon. The appointment of David Garcia as SVP of Finance was cited as a strategic move to strengthen financial oversight and capital markets engagement.

Guidance

CapsoVision aims to submit a next-generation AI analytics engine for regulatory approval by year-end 2025, pending FDA resumption of normal operations. The company anticipates advancing its colon-capsule program and expanding into new GI indications. With $17.8 million in cash and $23.4 million in net IPO proceeds, management expressed confidence in funding R&D and partnerships but provided no specific revenue or EPS guidance.

Additional News

CapsoVision submitted a Breakthrough Device Designation application to the FDA for its pancreatic cancer screening capsule, aiming to accelerate regulatory review. The company also appointed David Garcia as SVP of Finance, leveraging his capital markets expertise to support growth. Additionally, CapsoVision’s July 2025 IPO raised $23.4 million, bolstering its cash reserves and development pipeline.

About CapsoVision

CapsoVision is a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions. Its flagship product, CapsoCam Plus, enables non-invasive small-bowel imaging, with expansion plans into colon and pancreatic diagnostics. The company’s strategic partnerships and R&D focus position it to address unmet needs in GI diagnostics.

Forward-Looking Statements

This report contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including regulatory delays, technical challenges, and market conditions. Actual results may differ materially from those anticipated. Investors are advised to review CapsoVision’s SEC filings for a detailed discussion of risks.

Investor Relations Contact

Leigh Salvo

New Street Investor Relations

Investors@CapsoVision.com

Media Contact

Leslie Strickler and Paul Spicer

Être Communications

leslies@etrecommunications.com | (804) 240-0807